LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Search

ResMed Inc

Закрыт

СекторЗдравоохранение

252 0.44

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

249.71

Макс.

252.76

Ключевые показатели

By Trading Economics

Доход

44M

393M

Продажи

87M

1.4B

P/E

Средняя по отрасли

25.005

110.024

Дивидендная доходность

0.92

Рентабельность продаж

27.593

Сотрудники

10,600

EBITDA

63M

566M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+15.28% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.92%

2.26%

Следующий отчет о доходах

22 апр. 2026 г.

Дата следующей выплаты дивидендов

19 мар. 2026 г.

Следующая эксдивидендная дата

7 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-426M

37B

Предыдущая цена открытия

251.56

Предыдущая цена закрытия

252

Новостные настроения

By Acuity

17%

83%

23 / 351 Рейтинг в Healthcare

ResMed Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 февр. 2026 г., 23:07 UTC

Отчет

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 февр. 2026 г., 23:01 UTC

Отчет

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 февр. 2026 г., 22:59 UTC

Отчет

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

24 февр. 2026 г., 22:42 UTC

Отчет

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

24 февр. 2026 г., 22:24 UTC

Приобретения, слияния, поглощения

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

24 февр. 2026 г., 23:46 UTC

Обсуждения рынка

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

24 февр. 2026 г., 23:36 UTC

Обсуждения рынка

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

24 февр. 2026 г., 23:30 UTC

Обсуждения рынка

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

24 февр. 2026 г., 23:20 UTC

Обсуждения рынка

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

24 февр. 2026 г., 23:20 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

24 февр. 2026 г., 23:16 UTC

Отчет

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

24 февр. 2026 г., 23:13 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

24 февр. 2026 г., 23:12 UTC

Отчет

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

24 февр. 2026 г., 23:10 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

24 февр. 2026 г., 23:10 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

24 февр. 2026 г., 23:08 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

24 февр. 2026 г., 23:07 UTC

Отчет

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

24 февр. 2026 г., 22:52 UTC

Отчет

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

24 февр. 2026 г., 22:46 UTC

Отчет

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

24 февр. 2026 г., 22:31 UTC

Приобретения, слияния, поглощения

Warner Receives New Bid From Paramount -- 3rd Update

24 февр. 2026 г., 22:29 UTC

Отчет

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

24 февр. 2026 г., 22:28 UTC

Отчет

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

24 февр. 2026 г., 22:27 UTC

Отчет

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

24 февр. 2026 г., 22:27 UTC

Отчет

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

24 февр. 2026 г., 22:25 UTC

Отчет

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

24 февр. 2026 г., 22:24 UTC

Отчет

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

24 февр. 2026 г., 22:23 UTC

Отчет

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

24 февр. 2026 г., 22:22 UTC

Отчет

Woolworths Interim Dividend 45 Australian Cents/Share

24 февр. 2026 г., 22:22 UTC

Отчет

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

24 февр. 2026 г., 22:21 UTC

Отчет

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Сравнение c конкурентами

Изменение цены

ResMed Inc Прогноз

Целевая цена

By TipRanks

15.28% рост

Прогноз на 12 месяцев

Средняя 300.64 USD  15.28%

Максимум 345 USD

Минимум 265 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для ResMed Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

13 ratings

8

Покупка

5

Удержание

0

Продажа

Настроения

By Acuity

23 / 351Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
help-icon Live chat